skip to main content
DOE PAGES title logo U.S. Department of Energy
Office of Scientific and Technical Information

Title: A diagnostic microdosing approach to investigate platinum sensitivity in non-small cell lung cancer

Abstract

The platinum-based drugs cisplatin, carboplatin and oxaliplatin are often used for chemotherapy, but drug resistance is common. The prediction of resistance to these drugs via genomics is a challenging problem since hundreds of genes are involved. A possible alternative is to use mass spectrometry to determine the propensity for cells to form drug-DNA adducts—the pharmacodynamic drug-target complex for this class of drugs. In this paper, the feasibility of predictive diagnostic microdosing was assessed in non-small cell lung cancer (NSCLC) cell culture and a pilot clinical trial. Accelerator mass spectrometry (AMS) was used to quantify [14C]carboplatin-DNA monoadduct levels in the cell lines induced by microdoses and therapeutic doses of carboplatin, followed by correlation with carboplatin IC50 values for each cell line. The adduct levels in cell culture experiments were linearly proportional to dose (R2 = 0.95, p < 0.0001) and correlated with IC50 across all cell lines for microdose and therapeutically relevant carboplatin concentrations (p = 0.02 and p = 0.01, respectively). A pilot microdosing clinical trial was conducted to define protocols and gather preliminary data. Plasma pharmacokinetics (PK) and [14C]carboplatin-DNA adducts in white blood cells and tumor tissues from six NSCLC patients were quantified via AMS. The blood plasma half-lifemore » of [14C]carboplatin administered as a microdose was consistent with the known PK of therapeutic dosing. The optimal [14C]carboplatin formulation for the microdose was 107 dpm/kg of body weight and 1% of the therapeutic dose for the total mass of carboplatin. No microdose-associated toxicity was observed in the patients. Finally, additional accruals are required to significantly correlate adduct levels with response.« less

Authors:
 [1];  [2];  [1];  [1];  [3];  [3];  [3];  [4];  [5];  [6]; ORCiD logo [2]
  1. Univ. of California Davis, Sacramento, CA (United States). Division of Hematology and Oncology. Dept. of Internal Medicine. UC Davis Comprehensive Cancer Center
  2. Univ. of California Davis, Sacramento, CA (United States). Division of Hematology and Oncology. Dept. of Internal Medicine. UC Davis Comprehensive Cancer Center; Accelerated Medical Diagnostics Incorporated, Berkeley, CA (United States)
  3. Lawrence Livermore National Lab. (LLNL), Livermore, CA (United States)
  4. Accelerated Medical Diagnostics Incorporated, Berkeley, CA (United States)
  5. Univ. of California Davis, Sacramento, CA (United States). Dept. of Urology
  6. Univ. of California Davis, Sacramento, CA (United States). Division of Hematology and Oncology. Dept. of Internal Medicine. UC Davis Comprehensive Cancer Center. Dept. of Urology; VA Northern California Health Care System, Mather, CA (United States)
Publication Date:
Research Org.:
Lawrence Livermore National Lab. (LLNL), Livermore, CA (United States); Univ. of California Davis, Sacramento, CA (United States); Accelerated Medical Diagnostics Incorporated, Berkeley, CA (United States)
Sponsoring Org.:
USDOE; LLNL Laboratory Directed Research and Development (LDRD) Program; National Inst. of Health (NIH) (United States)
OSTI Identifier:
1438672
Report Number(s):
LLNL-JRNL-703560
Journal ID: ISSN 0020-7136
Grant/Contract Number:  
AC52-07NA27344; CA93373; HHSN261201000133C; HHSN261201200048C; P41 RR13461; 2P41GM103483-16
Resource Type:
Accepted Manuscript
Journal Name:
International Journal of Cancer
Additional Journal Information:
Journal Volume: 141; Journal Issue: 3; Journal ID: ISSN 0020-7136
Publisher:
Wiley
Country of Publication:
United States
Language:
English
Subject:
60 APPLIED LIFE SCIENCES; non-small cell lung cancer; platinum-based chemotherapy; diagnostic; microdosing; predictive diagnostics; accelerator mass spectrometry; biomarkers of response

Citation Formats

Wang, Si-Si, Zimmermann, Maike, Zhang, Hongyong, Lin, Tzu-yin, Malfatti, Michael, Haack, Kurt, Turteltaub, Kenneth W., Cimino, George D., de Vere White, Ralph, Pan, Chong-xian, and Henderson, Paul T. A diagnostic microdosing approach to investigate platinum sensitivity in non-small cell lung cancer. United States: N. p., 2017. Web. doi:10.1002/ijc.30747.
Wang, Si-Si, Zimmermann, Maike, Zhang, Hongyong, Lin, Tzu-yin, Malfatti, Michael, Haack, Kurt, Turteltaub, Kenneth W., Cimino, George D., de Vere White, Ralph, Pan, Chong-xian, & Henderson, Paul T. A diagnostic microdosing approach to investigate platinum sensitivity in non-small cell lung cancer. United States. doi:10.1002/ijc.30747.
Wang, Si-Si, Zimmermann, Maike, Zhang, Hongyong, Lin, Tzu-yin, Malfatti, Michael, Haack, Kurt, Turteltaub, Kenneth W., Cimino, George D., de Vere White, Ralph, Pan, Chong-xian, and Henderson, Paul T. Mon . "A diagnostic microdosing approach to investigate platinum sensitivity in non-small cell lung cancer". United States. doi:10.1002/ijc.30747. https://www.osti.gov/servlets/purl/1438672.
@article{osti_1438672,
title = {A diagnostic microdosing approach to investigate platinum sensitivity in non-small cell lung cancer},
author = {Wang, Si-Si and Zimmermann, Maike and Zhang, Hongyong and Lin, Tzu-yin and Malfatti, Michael and Haack, Kurt and Turteltaub, Kenneth W. and Cimino, George D. and de Vere White, Ralph and Pan, Chong-xian and Henderson, Paul T.},
abstractNote = {The platinum-based drugs cisplatin, carboplatin and oxaliplatin are often used for chemotherapy, but drug resistance is common. The prediction of resistance to these drugs via genomics is a challenging problem since hundreds of genes are involved. A possible alternative is to use mass spectrometry to determine the propensity for cells to form drug-DNA adducts—the pharmacodynamic drug-target complex for this class of drugs. In this paper, the feasibility of predictive diagnostic microdosing was assessed in non-small cell lung cancer (NSCLC) cell culture and a pilot clinical trial. Accelerator mass spectrometry (AMS) was used to quantify [14C]carboplatin-DNA monoadduct levels in the cell lines induced by microdoses and therapeutic doses of carboplatin, followed by correlation with carboplatin IC50 values for each cell line. The adduct levels in cell culture experiments were linearly proportional to dose (R2 = 0.95, p < 0.0001) and correlated with IC50 across all cell lines for microdose and therapeutically relevant carboplatin concentrations (p = 0.02 and p = 0.01, respectively). A pilot microdosing clinical trial was conducted to define protocols and gather preliminary data. Plasma pharmacokinetics (PK) and [14C]carboplatin-DNA adducts in white blood cells and tumor tissues from six NSCLC patients were quantified via AMS. The blood plasma half-life of [14C]carboplatin administered as a microdose was consistent with the known PK of therapeutic dosing. The optimal [14C]carboplatin formulation for the microdose was 107 dpm/kg of body weight and 1% of the therapeutic dose for the total mass of carboplatin. No microdose-associated toxicity was observed in the patients. Finally, additional accruals are required to significantly correlate adduct levels with response.},
doi = {10.1002/ijc.30747},
journal = {International Journal of Cancer},
number = 3,
volume = 141,
place = {United States},
year = {2017},
month = {4}
}

Journal Article:
Free Publicly Available Full Text
Publisher's Version of Record

Citation Metrics:
Cited by: 4 works
Citation information provided by
Web of Science

Save / Share:

Works referenced in this record:

Comparison of Four Chemotherapy Regimens for Advanced Non–Small-Cell Lung Cancer
journal, January 2002

  • Schiller, Joan H.; Harrington, David; Belani, Chandra P.
  • New England Journal of Medicine, Vol. 346, Issue 2
  • DOI: 10.1056/NEJMoa011954

Adaptive Randomization of Veliparib–Carboplatin Treatment in Breast Cancer
journal, July 2016

  • Rugo, Hope S.; Olopade, Olufunmilayo I.; DeMichele, Angela
  • New England Journal of Medicine, Vol. 375, Issue 1
  • DOI: 10.1056/NEJMoa1513749

The resurgence of platinum-based cancer chemotherapy
journal, July 2007

  • Kelland, Lloyd
  • Nature Reviews Cancer, Vol. 7, Issue 8
  • DOI: 10.1038/nrc2167

Association of genetic polymorphisms in the base excision repair pathway with lung cancer risk: A meta-analysis
journal, December 2006


Pharmacogenetics of the DNA repair pathways in advanced non-small cell lung cancer patients treated with platinum-based chemotherapy
journal, October 2014


Cellular processing of platinum anticancer drugs
journal, March 2005

  • Wang, Dong; Lippard, Stephen J.
  • Nature Reviews Drug Discovery, Vol. 4, Issue 4
  • DOI: 10.1038/nrd1691

The NCI60 human tumour cell line anticancer drug screen
journal, October 2006

  • Shoemaker, Robert H.
  • Nature Reviews Cancer, Vol. 6, Issue 10
  • DOI: 10.1038/nrc1951

DNA-adduct levels as a predictor of outcome for NSCLC patients receiving daily cisplatin and radiotherapy
journal, March 2000


Platinum—DNA damage in leukocyte DNA of patients receiving carboplatin and cisplatin chemotherapy, measured by atomic absorption spectrometry
journal, January 1991


Molecular determinants of irinotecan efficacy
journal, August 2006

  • Vallböhmer, Daniel; Iqbal, Syma; Yang, Dong Yun
  • International Journal of Cancer, Vol. 119, Issue 10
  • DOI: 10.1002/ijc.22129

A microdosing approach for characterizing formation and repair of carboplatin-DNA monoadducts and chemoresistance
journal, March 2011

  • Henderson, Paul T.; Li, Tao; He, Miaoling
  • International Journal of Cancer, Vol. 129, Issue 6
  • DOI: 10.1002/ijc.25814

Efficacy of Carboplatin Alone and in Combination with ABT888 in Intracranial Murine Models of BRCA-Mutated and BRCA-Wild-Type Triple-Negative Breast Cancer
journal, March 2015


Clinical Pharmacokinetics of Carboplatin
journal, January 1991


Computed Tomography — An Increasing Source of Radiation Exposure
journal, November 2007

  • Brenner, David J.; Hall, Eric J.
  • New England Journal of Medicine, Vol. 357, Issue 22
  • DOI: 10.1056/NEJMra072149

Predictive biomarkers in patients with resected non-small cell lung cancer treated with perioperative chemotherapy
journal, November 2013


The measurement of cisplatin-DNA adduct levels in testicular cancer patients
journal, January 1988


Protein interactions with platinum–DNA adducts: from structure to function
journal, October 2004


Cisplatin Resistance: A Cellular Self-Defense Mechanism Resulting from Multiple Epigenetic and Genetic Changes
journal, June 2012

  • Shen, Ding-Wu; Pouliot, Lynn M.; Hall, Matthew D.
  • Pharmacological Reviews, Vol. 64, Issue 3
  • DOI: 10.1124/pr.111.005637

Personalized medicine for targeted and platinum-based chemotherapy of lung and bladder cancer
journal, February 2013

  • Cimino, George D.; Pan, Chong-xian; Henderson, Paul T.
  • Bioanalysis, Vol. 5, Issue 3
  • DOI: 10.4155/bio.12.325

Microdose-Induced Drug–DNA Adducts as Biomarkers of Chemotherapy Resistance in Humans and Mice
journal, November 2016


Rapid colorimetric assay for cellular growth and survival: Application to proliferation and cytotoxicity assays
journal, December 1983


Cisplatin in cancer therapy: Molecular mechanisms of action
journal, October 2014


Q-Gene: processing quantitative real-time RT-PCR data
journal, July 2003


Tissue Platinum Concentration and Tumor Response in Non–Small-Cell Lung Cancer
journal, September 2012


Epidemiology of Lung Cancer
journal, July 2016

  • Mao, Yousheng; Yang, Ding; He, Jie
  • Surgical Oncology Clinics of North America, Vol. 25, Issue 3
  • DOI: 10.1016/j.soc.2016.02.001

Relationship between the exposure to cisplatin, DNA-adduct formation in leucocytes and tumour response in patients with solid tumours
journal, June 1996

  • Schellens, Jhm; Ma, J.; Planting, ASTh
  • British Journal of Cancer, Vol. 73, Issue 12
  • DOI: 10.1038/bjc.1996.296

Clinical Pharmacokinetics and Dose Optimisation of Carboplatin
journal, January 1997


Cisplatin versus carboplatin: comparative review of therapeutic management in solid malignancies
journal, June 2016


Analysis of cytotoxicities of platinum compounds
journal, July 2005

  • Goodisman, Jerry; Hagrman, Douglas; Tacka, Kirk A.
  • Cancer Chemotherapy and Pharmacology, Vol. 57, Issue 2
  • DOI: 10.1007/s00280-005-0041-4

The status of platinum anticancer drugs in the clinic and in clinical trials
journal, January 2010

  • Wheate, Nial J.; Walker, Shonagh; Craig, Gemma E.
  • Dalton Transactions, Vol. 39, Issue 35
  • DOI: 10.1039/c0dt00292e

Emerging concepts on drug resistance in bladder cancer: Implications for future strategies
journal, October 2015


Platinum-DNA adducts in leukocyte DNA correlate with disease response in ovarian cancer patients receiving platinum-based chemotherapy.
journal, July 1987

  • Reed, E.; Ozols, R. F.; Tarone, R.
  • Proceedings of the National Academy of Sciences, Vol. 84, Issue 14
  • DOI: 10.1073/pnas.84.14.5024

DNA damage induced by cis- and carboplatin as indicator for in vitro sensitivity of ovarian carcinoma cells
journal, October 2009

  • Unger, Florian T.; Klasen, Hermann A.; Tchartchian, Garri
  • BMC Cancer, Vol. 9, Issue 1
  • DOI: 10.1186/1471-2407-9-359

Platinum drug-DNA interactions in human tissues measured by cisplatin-DNA enzyme-linked immunosorbent assay and atomic absorbance spectroscopy.
journal, March 1993

  • Poirier, M. C.; Reed, E.; Shamkhani, H.
  • Environmental Health Perspectives, Vol. 99
  • DOI: 10.1289/ehp.9399149

Blood clearance of radioactively labelled cis-diammine 1,1-cyclobutane dicarboxylate platinum(II) (CBDCA) in cancer patients
journal, August 1983

  • Sharma, H.; Thatcher, N.; Baer, J.
  • Cancer Chemotherapy and Pharmacology, Vol. 11, Issue 1
  • DOI: 10.1007/BF00257407

    Works referencing / citing this record:

    Radiocarbon Tracers in Toxicology and Medicine: Recent Advances in Technology and Science
    journal, May 2019

    • Malfatti, Michael A.; Buchholz, Bruce A.; Enright, Heather A.
    • Toxics, Vol. 7, Issue 2
    • DOI: 10.3390/toxics7020027

    Radiocarbon Tracers in Toxicology and Medicine: Recent Advances in Technology and Science
    journal, May 2019

    • Malfatti, Michael A.; Buchholz, Bruce A.; Enright, Heather A.
    • Toxics, Vol. 7, Issue 2
    • DOI: 10.3390/toxics7020027